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A B S T R A C T
Introduction: Oral cancer is a serious public health issue. Apart from its high rate of prevalence, incidence and
mortality, it can often result in more complex and expensive treatment when diagnosed late. Potentially ma-
lignant disorders (PMDs) can precede oral cancer, and are usually treated by surgical excision. However, in many
cases patients are elderly and multiple interventions may be required. Photodynamic therapy (PDT) is a simple
alternative, which has been successfully used in the treatment of oral PMDs.
Objective: Due to the lack of standardization regarding photosensitizers (PTSs), types of irradiation, and methods
of application, the objective of this study was to analyze existing PDT protocols in an attempt to identify the one
that demonstrates greater eﬃciency, reliability and feasibility in the treatment of oral PMDs for both researchers
and clinicians.
Methods: Original clinical studies published only in English between 1993 and 2016 were searched in Pubmed/
Medline database using the following keywords: photodynamic therapy; oral potentially malignant disorder; oral
premalignant lesions. Review articles; experimental studies; case-reports; commentaries; and letters to the Editor
were excluded from the selection.
Results and conclusion: Based on the 16 studies selected, the topical 5-ALA-20% PTS, associated to a LED light
applied for 15 min with a 7-day interval between sessions emerged as the most frequently used PDT protocol,
with satisfactory results. Due to its low rate of side eﬀects, this PDT protocol presents good potential for the
treatment of oral PMDs. Further clinical studies are required to ascertain its long-term validity in preventing oral
cancer.
1. Introduction
Potentially malignant disorders (PMDs) refer to benign, but mor-
phologically altered tissues, which present a greater risk of undergoing
malignant transformations [1]. The World Health Organization (WHO),
in 2005, changed the previous terminology “potentially malignant le-
sions” and “potentially malignant conditions” to PMD [2].
The term dysplasia is characterized by the presence ofysplasia is
characterized by the presence of abnormal epithelial architecture, dis-
ordered cell growth, changes in the nuclear-cytoplasmic ratio, atypical
mitosis, and other alterations. Dysplasia can be classiﬁed into mild,
moderate, and intense, according to subjective microscopic analysis
[3]. It is believed that the more severe the epithelial dysplasia, the
greater the risk of malignization [3].
Oral PMD management still requires clearer deﬁnition. Surgical
excision, laser surgery, and cryotherapy associated with the reduction
of risk factors, as well as follow up examinations for diﬀerent periods of
time have been suggested [2,4,5]. Photodynamic therapy (PDT) has
recently emerged as a potential alternative in the treatment of PMDs,
since it is capable of promoting total or partial regression of these
conditions with few side eﬀects [2,4,5].
1.1. Photodynamic therapy
PDT is a minimally invasive treatment, successfully applied in head
and neck PMDs and malignant disorders. The technique is simple and
can usually be performed on an outpatient basis [4,5].
A topical or systemic photosensitizer (PTS) drug is administered,
which selectively binds to atypical cells. After an incubation period, a
source of light of suitable wavelength is applied on the target tissue. It
promotes the absorption of photons by the PTS, which turns into an
extremely unstable molecule [6]. This molecule, while searching for
stability, transfers the light energy to the oxygen in the cellular en-
vironment. This reaction generates oxygen reactive species, which has a
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cytotoxic eﬀect on the tissue, leading to cell death [6].
When compared to more invasive techniques, PDT systemic eﬀects
are insigniﬁcant, it is minimally toxic to normal tissue, and presents
reduced morbidity and excellent aesthetic results. It can be applied in
association with any other conventional treatment and repeated as
often as necessary, without generating cumulative toxicity [4–6]. Sen-
sitivity, pain, swelling, burning sensation, taste alterations, ulcerations,
and loss of local sensation have been reported with PDT, but often with
a low magnitude [7,8].
1.2. Photosensitizer
Photosensitizers (PTSs) are drugs that promote the transfer of light
energy to the cellular environment, resulting in the formation of highly
reactive chemical species, which act in the destruction of target cells.
PTSs tend to accumulate in atypical cells, but the mechanisms re-
sponsible for this process are not completely understood [6]. Several
hypotheses have been proposed. One of them concerns the pre-
dominance of blood vessels with morphological changes in tumors as a
result of neovascularization and the lack of lymphatic drainage,
creating greater permeability and drug retention [6]. Another hypoth-
esis states that some drugs preferentially bind to low-density-lipopro-
tein (LDL) receptors, which are over-expressed in atypical cells [6].
There is also the perception that low pH found in atypical cells cyto-
plasm promotes drug ionization, making it more hydrophilic, increasing
PTS retention inside the cell [9].
To select the appropriate PTS for each clinical situation, features
such as toxicity, selectivity, wavelength necessary for its activation,
eﬀectiveness, side eﬀects, route of administration and cost have to be
taken into consideration.
There are three generations of drugs, according to their chron-
ological order of development. The ﬁrst generation includes hemato-
porphyrin derivative (HpD) and porﬁmer sodium (Photofrin®) [6]. To
improve some of drawbacks presented by the ﬁrst generation of PTSs
(relatively low absorption and skin photosensitivity), the second gen-
eration of PTSs was developed, with excellent results [6]. It includes 5-
aminolevulinic acid (5-ALA); hypericin; phthalocyanine; benzopor-
phyrin derivatives, such as Verteporﬁn®; and meta tetrahydroxyphenyl
chlorin (mTHPC) derivatives, such as Foscan® [6]. A new, third gen-
eration of PTSs is now being developed to improve atypical cell se-
lectivity, and represents an area of active research [6].
1.2.1. Light sources
The application of light in an appropriate wavelength
(600–800 nm), also known as the “therapeutic window”, excites the
PTS, generating a reaction with the oxygen present in the cells. Shorter
wavelengths have low tissue penetration, while irradiation with longer
wavelengths may not have enough power to generate reactive oxygen
[6]. The blue light (450–495 nm), for example, penetrates less eﬃ-
ciently through the tissue when compared to the red (620–750 nm) and
infrared light (> 750 nm), which can penetrate deeper in the tissue [6].
The choice of a light source is dependent on the lesion (tissue fea-
ture, size, location and accessibility), type of PTS (spectrum of ab-
sorption and administration), cost and availability of light systems [6].
Theoretically, any light source may be used in PDT [10]. Conven-
tional lamps were the ﬁrst to be used. Because they have a wide range
of wavelengths, ﬁlters are required to obtain the desired wavelength
[10]. With the introduction of lasers, the use of conventional lamps in
PDT has decreased considerably [11]. Laser produces monochromatic
wavelengths, which allows easy calculation of light dosimetry and the
ideal wavelength for a speciﬁc PTS [11]. The light-emitting diode (LED)
is also an alternative source of light that has been increasingly used [6].
1.2.2. Photochemistry and photophysics
The basic principle of PDT is the formation of cytotoxic agents from
the interaction of the oxygen within the cells and the PTS excited by
light of an appropriate wavelength.
After activation by light photons, the PTS changes from its primary
state (1PTS) to a singlet excited-state (1PTS*) [12]. The excited PTS is
very unstable and tends to return to its original and energetically more
favorable state, which takes place through the emission of heat or
ﬂuorescence [12]. In this particular case, photodynamic reactions with
therapeutic outcomes do not occur, but have the potential to be used as
a diagnostic tool [12]. Another possibility is the passage of 1PTS* to
another excitation state, less unstable, called triplet state (3PTS*),
which is capable of promoting two diﬀerent photodynamic reactions
[12]:
Type I reaction – PTS in its excited triplet state (3PTS*) interacts
with cellular substrates [6,12]. Through the transfer of electrons, ions
are generated. These react with molecular oxygen, making reactive
oxygen species (ROS), such as superoxide, hydrogen peroxide and hy-
droxyl radicals [6,12].
Type II reaction – Direct transfer of energy between 3PTS* and
molecular oxygen occurs, exciting O2 and leading to the formation of
singlet oxygen (1O2), which is also a ROS [6,12].
Reactive oxygen species are highly reactive free radicals, which
have the ability to interact with diﬀerent molecules and damage their
normal function [13]. This is a key factor for PDT cytotoxicity [13].
ROS formation can lead to tumor destruction through three main bio-
logical mechanisms: 1) direct destruction by activating cell death
pathways, such as apoptosis, necrosis and autophagy; 2) damage to the
tumor vasculature, by suppressing the delivery of oxygen and nutrients;
and 3) stimulation of inﬂammatory and/or immune response [13].
2. Methodology
Original clinical studies, published only in English between 1993
and 2016 were searched in Pubmed/Medline database using diﬀerent
combinations of the following keywords: photodynamic therapy; oral
potentially malignant disorder; oral premalignant lesion. Sixteen clin-
ical studies using PDT to treat oral PMD were selected. The objective
was to compare the PDT protocols used and their respective results.
Review articles, experimental studies (in vitro or animal studies), case-
reports, commentaries, and letters to the Editor were excluded from the
selection.
3. Results
The selected articles are displayed in Table 1.
Based on the selected studies, a comparative analysis of the proto-
cols and their respective results was performed. Absence or incomplete
data were disregarded.
Methodological diﬃculties were found during table organization. In
Kübler et al. [16], Tsai et al. [17], Rigual et al. [22] and Shaﬁrstein
et al. [8], for example, the number of sessions, time of light activation
and interval among sessions were absent. In Yu et al. [21], Lin et al.
[23], Pietruska et al. [24] the type of laser was not described, and in
Fan et al. [15], Tsai et al. [17], Pietruska et al. [24] and Maloth et al.
[26] the number of recurrences was not disclosed.
Number of sessions ranged from 1 to 10; light application time from
10 to 16.6 min; and the interval among sessions ranged from 3.5 to 14
days, with the 7-day interval being the most frequent [4,7,14–16]. The
time from PTS administration and light activation was between 48 and
96 h when used intravenously; 1.5–4 h when applied topically; 0.5–4 h
orally; and 1.5 h for intralesional application [4,7,14–16].
Light dose administered ranged from 50 to 200 J/cm2. The most
frequent was 100 J/cm2, used in 10 of the 16 studies
[7,8,16–21,23,25]. In four studies, the light dose administered was
variable [4,14,15,22]. Grant [14] used 50–100 J/cm2; Fan et al. [15],
100–200 J/cm2; Rigual et al. [22], 50–75 J/cm2 and Jerjes et al. [4]
used 100–200 J/cm2 [4,14,15,22].
Regarding the PTS, the most frequently used drug was the 5-
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aminolevulinic acid (5-ALA) 20% (Levulan®), applied topically in 8 of
the 16 studies [8,16,17–21,23]. The 5-ALA was applied in a total of 256
patients, with complete remission in 78% of the lesions, partial remis-
sion in 18% and no remission in 6%. The recurrence rate was 7%.
3.1. Discussion
The 5-aminolevulinic acid (5-ALA) is a prodrug that undergoes
biotransformation and only becomes active in vivo. It quickly accu-
mulates in large quantities in tissues [27]. This feature is one of the
major advantages of 5-ALA compared to other PTSs, and may explain
why it has been more frequently used [27]. With 5-ALA, side eﬀects
tend to be reduced, since its clearance is faster than other PTSs [28]. It
is used topically in the treatment of surface lesions, such as oral PMD,
and is capable of penetrating 1–2 mm into the tissues [29].
LED (5 studies) and diode laser (4 studies) were the most frequently
used light sources [4,8,19–22,26]. One study using 5-ALA compared
LED and Laser in oral PMD, ﬁnding no signiﬁcant diﬀerences between
the light sources [21]. According to the authors, LED was simpler,
lighter, smaller, more portable, and cheaper with the potential to re-
place Laser in the future. However, the authors call attention to its
durability, which may be compromised by chip impairment as a result
of the heat generated [21]. The Laser source (speciﬁcation not pro-
vided), on the other hand, was considered more stable, more durable
and was equipped with adjustable power, although it was heavier and
more expensive [21]. The authors concluded that when used in ery-
throleukoplakia, the choice of the light source would depend on the
budget [21].
No explanation is available for the existence of varied responses
using the same PDT protocol. Probably the results are inﬂuenced by
speciﬁc features of PMDs such as size, color, presence of atypia and
thickness of the keratin layer. Best results were achieved in minor le-
sions and with thinner keratin layers [8,20,21,23,25]. For example, a
study reported better clinical outcome for dysplastic erythroleukoplakia
lesions than for non-dysplastic oral lesions such as leukoplakia lesions
[21]. The histological, biological and structural characteristics of ery-
throleukoplakia contribute to the successful clinical outcome of these
lesions. Compared to non-dysplastic oral lesions, dysplastic ery-
throleukoplakia lesions have less keratotic epithelial surface, as well as
thinner and more permeable epithelium. Thus, the topical PTS may
more easily diﬀuse into these dysplastic epithelia, resulting in good
absorption, while the reducing eﬀect of the thinner keratin layer on
light intensity was minimal [21].
The measures adopted in case of recurrence were the repetition of
the PDT protocol, lesion excision or just follow-up, depending on the
lesion or patient’s wish [4,14,21–23].
PDT side eﬀects are uncommon. Mild to moderate pain and local
edema were the most reported eﬀects [4,7,8,14,15,17,20,22,23]. Skin
photosensitivity, burning sensation and discomfort were also common
[4,8,15,16,20,22–24,25]. Although not frequent, erythema, ulceration
and secondary infection were also present [7,8,16,17]. For pain control,
nonsteroidal anti-inﬂammatory drugs (NSAIDs) and opiates were con-
sidered suﬃcient [4,5]. Systemic PTS resulted in some important side
eﬀects, when compared to topical PTS, such as residual systemic pho-
tosensitization, which can last for several days or weeks, edema, sun-
burn and superﬁcial skin necrosis, when skin is exposed to bright light
[4].
PDT consists of an eﬀective, non-toxic strategy in the treatment of
oral PMDs. It is a minimally invasive technique that results in less
morbidity and mutilation to the oral tissues, and can be applied several
times, with minimal side eﬀects. However, standardized protocols,
clinical trials with larger samples, as well as long term follow-ups are
still required.
4. Conclusion
PMDs are a therapeutic challenge for dental surgeons. Based on the
short-term clinical applicability and the beneﬁts demonstrated, PDT can
be a useful treatment strategy for the management of oral PMDs. Based
on the literature review conducted, the protocol using 5-ALA-20% to-
pical PTS in association with a LED light source, applied for 15 min
with 7-day intervals between sessions, the number of sessions de-
pending on the response to the treatment, emerged as a strong candi-
date in the treatment of PMDs. The use of systemic sensitizer (Porﬁmer
sodium 2 mg/kg) yielded an initial complete response rate of 90%,
which surely would also warrant its inclusion in any anticipated clinical
trials. However, due to the side eﬀects resulting from its use, and the
small size of oral lesions compared to skin lesions, topical use seems to
be best indicated in oral PMDs. It should be noted, however, that the
primary aim of PDT is to prevent invasive malignancy occurring.
Invasive tumors often arise in apparently normal areas of the mucosa so
that it cannot be anticipated that the resolution of obvious oral PMDs
will actually avoid the development of cancer. Further clinical studies
with long term follow up are required to determine not only the best
protocol, but also the ultimate beneﬁts of PDT in the treatment of oral
PMDs.
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